EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population

Sang Kun Lee iD, Peimin Yu iD, Eunyeong Choe, Louis Ferrari iD, Kyoung Heo iD, Seung Bong Hong iD, Zhen Hong iD, Koji Iida iD, Yong Heui Jeon iD, Jiwon Jung, Marc Kamin, Kensuke Kawai iD und 9 weitere

Epilepsia · 28.08.2026

DOI: 10.1002/epi.70459 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, online erschienen am 28.08.2026. Verfasst von Sang Kun Lee und 20 weiteren Autor:innen. Beteiligte Einrichtung: National University College of Medicine, Seoul, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SK Life Science, SK Biopharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to assess long‐term efficacy, safety, and tolerability of adjunctive cenobamate in an open‐label extension (OLE) of a randomized, double‐blind, placebo‐controlled, dose–response study (NCT04557085; YKP3089C035 [Study C035]) in Asian patients with uncontrolled focal seizures.

Methods

Patients 18–70 years old with uncontrolled focal seizures despite treatment with 1–3 antiseizure medications who completed the 24‐week double‐blind treatment period ( n = 425) at cenobamate doses of 100, 200, or 400 mg/day or placebo could enter a 52‐week OLE. All patients were converted to a cenobamate dose of 400 mg/day during a 20‐week double‐blind conversion phase and then entered a 32‐week open‐label maintenance phase at a starting dose of 300 mg/day.

Results

Among the 410 patients who entered the double‐blind conversion phase, 357 (263 and 94 originally randomized to cenobamate and placebo, respectively) entered the OLE maintenance phase. The median percent focal seizure frequency reduction from double‐blind baseline for patients who received at least one dose of cenobamate during the 32‐week maintenance phase was 83.6%. The percent of patients achieving ≥50% and 100% responses during the maintenance phase was 75.1% and 25.5%, respectively. Among patients entering the OLE, 84.6% (347/410) completed the 52 weeks of treatment with cenobamate. The most commonly occurring treatment‐emergent adverse events (TEAEs) during the entire OLE were dizziness, somnolence, γ‐glutamyl transferase (GGT) increase, and COVID‐19 infection. GGT increase was not associated with any clinically significant findings. Serious TEAEs occurred in 11.7% of patients (48/410). There were no deaths and no cases of DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome reported. Significance The high long‐term seizure frequency reductions, including a 100% responder rate of 25.5%, were consistent with previous long‐term cenobamate efficacy. The OLE safety profile was also generally consistent with the known cenobamate safety profile, with no new safety signals identified. These results support the use of cenobamate in adult Asian patients with uncontrolled focal seizures.

Schlagwörter

Stichwörter der Autor:innen

cenobamateefficacyfocal seizureslong termsafety/tolerability

Autor:innen und Institutionen

  • National University College of Medicine, Seoul, Republic of Korea.
  • Huashan Hospital, Fudan University, Shanghai, China.
  • SK Biopharmaceuticals Co., Seongnam, Republic of Korea.
  • SK Life Science, Paramus, New Jersey, USA.
  • Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Epilepsy & Sleep Center, St. Peter's General Hospital, Seoul, Republic of Korea.

ORCID-Profile: Sang Kun Lee, Peimin Yu, Louis Ferrari, Kyoung Heo, Seung Bong Hong, Zhen Hong, Koji Iida, Yong Heui Jeon, Kensuke Kawai, Ji Hyun Kim, Xiaorong Liu, Jungshin Park, William Rosenfeld, Takamichi Yamamoto, Dong Zhou, Suiqiang Zhu, Sunita N Misra

Förderung

  • SK Life Science
  • SK Biopharmaceuticals

Zitieren

APA

Lee, S. K., Yu, P., Choe, E., Ferrari, L., Heo, K., Hong, S. B., Hong, Z., Iida, K., Jeon, Y. H., Jung, J., Kamin, M., Kawai, K., Kim, J. H., Kim, M. W., Liu, X., Park, J., Rosenfeld, W., Yamamoto, T., Zhou, D., …, & Misra, S. N. (2026). Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population. Epilepsia. https://doi.org/10.1002/epi.70459

Vancouver

Lee SK, Yu P, Choe E, Ferrari L, Heo K, Hong SB, et al. Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population. Epilepsia. 2026. doi:10.1002/epi.70459

BibTeX
@article{Lee2026,
  author = {Lee, Sang Kun and Yu, Peimin and Choe, Eunyeong and Ferrari, Louis and Heo, Kyoung and Hong, Seung Bong and Hong, Zhen and Iida, Koji and Jeon, Yong Heui and Jung, Jiwon and Kamin, Marc and Kawai, Kensuke and Kim, Ji Hyun and Kim, Myung Won and Liu, Xiaorong and Park, Jungshin and Rosenfeld, William and Yamamoto, Takamichi and Zhou, Dong and Zhu, Suiqiang and Misra, Sunita N},
  title = {Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population},
  journal = {Epilepsia},
  year = {2026},
  doi = {10.1002/epi.70459}
}
Kostenlos starten →